• The increase of cancer survival remains curtailed by cardiovascular mortality.
Essentials
• The increase of cancer survival remains curtailed by cardiovascular mortality.
• We studied a large range of inflammatory and coagulation biomarkers in long-term cancer survivors.
• Cancer history has an important impact on mortality independent of cardiovascular risk factors.
• Fibrinogen and von Willebrand factor are potential biomarkers in survivors of increased mortality.
Summary. Background: The advances in cancer treatment and detection of early cancer have resulted in a steady increase in the number of of cancer survivors over the years. However, because of the long-term toxic effects of chemotherapy and radiotherapy, the incidence of cardiovascular disease (CVD) is increasing in survivors. Objectives: To investigate traditional cardiovascular risk factors (CVRFs), inflammation and the coagulation profile in long-term cancer survivors (cancer diagnosis ≥ 5 years) from a large adult population-based study sample. Methods: The presence of cardiovascular risk factors (CVRFs) and laboratory markers were compared in individuals with (n = 723) and without (n = 13626) a long-term history of cancer from the Gutenberg Health Study. Data on coagulation factors, D-dimer and von Willebrand factor (VWF) activity were available for 4974 individuals (n = 244 cancer survivors). Results: In multivariable regression models, a history of cancer was, independently of CVRFs and CVD, associated with higher fibrinogen levels (b 6.99, 95% confidence interval [CI] 1. 16-12.8) , VWF activity (b 5.08, 95% CI 0.02-10.1), and antithrombin activity (b 1.85, 95% CI 0.44-3.27). Cancer survivors with CVD showed notably higher VWF activity than individuals with CVD without a history of cancer, with a difference in the means of 23.0 (7.9-38.1). Multivariate Cox regression analysis, adjusted for CVRFs, confirmed that a long-term history of cancer is associated with a 72% higher mortality. Increased mortality in cancer survivors was dependent on fibrinogen level and VWF activity level. Conclusion: Cancer survivors showed a worse inflammation and coagulation profile than individuals without a history of cancer. Overall mortality in long-term cancer survivors was increased independently of traditional CVRFs. These results underline the need to further investigate plasma biomarkers as complementary cardiovascular risk predictors in cancer survivors.
Introduction
Cancer is among the leading causes of morbidity and mortality worldwide, with 14 million new cases and accounting for 8.2 million deaths in 2012 [1] . It has been estimated that nearly 51% of men and 43% of women in Germany will develop cancer during their lifetime [2] . The advances in treatment and improved detection of early cancers have resulted in a steady increase in the number of cancer survivors over the years. On the basis of the epidemiological projections, there will be 11.8 million cancer survivors in the USA by the year 2020, representing a 42% increase in a 10-year time frame (2010-2020) [3] . Despite these improvements, the increase in cancer survival remains curtailed by cardiovascular mortality, particularly in long-term survivors, in whom the consequences of anticancer treatment become dominant [4] [5] [6] . In addition, low socioeconomic status of cancer patients was linked to a higher risk of serous comorbidity and worse survival [7] . The high variability in the response to the same cancer treatment and related toxicity can be correlated with the gene polymorphisms and genetic alterations affecting the metabolism of drugs [8] .
The long-term impact of toxic side effects of chemotherapy and radiotherapy, linked to common risk factors or the coexistence of both diseases in the aging population, have all been implicated in the cancer-cardiovascular disease (CVD) relationship. Vascular conditions, including premature atherosclerosis, arterial thrombosis, and venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and/or pulmonary embolism (PE), are commonly described in these patients [9] .
Cancer and CVD share acute and chronic inflammation and associated hypercoagulability as a possible major unifying risk factor, as well as a biologically relevant mechanism involved in the etiology of both pathologies [10] . At present, the implications of inflammation in promoting carcinogenesis and cancer progression are well appreciated [11] . Inflammation also mediates all stages of atherosclerosis, which is the underlying condition in most cardiovascular events, from onset to atherothrombosis [12] . Inflammation is closely linked to hypercoagulability, and the complex crosstalk between the two systems, i.e. coagulation and inflammation, has been under extensive investigation [13] . Whereas hypercoagulability is a key feature in VTE, it also promotes atherogenesis in experimental studies, and has been associated with atherosclerosis and atherothrombotic complications in humans [14, 15] . To a significant extent, hypercoagulability is driven by inflammation and mediated by coagulation protein-accelerated thrombin and fibrin generation. Although these mechanisms have been linked with active malignancy and thrombosis, much less is known about what the impact of a history of cancer in cancer survivors may be on the long-term bidirectional inflammation-coagulation axis, especially in relation to present CVD. This is even more important now, as cancer survival may further improve with novel targeted therapy, but the risks of vascular and other toxicity are not decreasing [16] . This situation creates the need to identify risk factors and individuals at risk, so that strategies and interventions can be employed to reduce the excess burden of CVD in this vulnerable population.
The Gutenberg Health Study (GHS), designed as a population-based, prospective, observational, single-center cohort study in the Rhine-Main region of Germany, offers the potential to explore the associations of inflammatory and coagulation biomarkers, as well as multiple cardiovascular risk factors (CVRFs), in long-term survivors of cancer. The prospective nature of this study also offers the potential to investigate the impact of a longterm history of cancer on total mortality in the general population.
Methods

Study design and participants
The GHS was conceptualized primarily to investigate CVD in individuals living in Mainz and Mainz-Bingen County, Germany, randomly selected from the governmental registry, who were stratified for sex, decade of age, and residence (urban versus rural). In the period between April 2007 and April 2012, 15 010 participants aged 35-74 years at their baseline examination were enrolled. All participants underwent a 5-h comprehensive examination at the study center at the University Medical Center in Mainz, according to the standard operating procedures. Details of the study design have been published previously [17] . The project was approved by the local ethics committee, and written informed consent was obtained from all participants before they entered the study. The study was conducted in accordance with the Declaration of Helsinki.
History of cancer, type of cancer, the date of the first cancer diagnosis and the date of the second cancer diagnosis were self-reported or obtained from medical records whenever available. Overall, 705 individuals of the total 15 010 reported a cancer diagnosed 5 years prior to the examination. The median survival time was 7.48 years (6.1-8.8 years). Cancer survivors with a time from diagnosis of < 5 years (N = 485) and diagnosed with a rare cancer (N = 77) or local malignant tumour (including non-melanoma skin tumours, N = 74), survivors without information on the time from cancer diagnosis (N = 18) and individuals with missing data for history of cancer (N = 25) were excluded from the analysis.
Definition of classical CVRFs and CVD
Obesity has been defined as a body mass index of ≥ 30 kg m À ². Individuals were classified as smokers (daily smokers, ≥ 1 cigarette per day; occasional smokers, < 1 cigarette per day), former smokers, and non-smokers (never smoked). Diabetes mellitus, dyslipidemia and hypertension were considered to be present in individuals with a definite diagnosis by a physician. In addition, diabetes mellitus was defined as a blood glucose level of ≥ 126 mg dL À1 in the baseline examination after an overnight fast of at least 8 h or a blood glucose level of ≥ 200 mg dL À1 in the baseline examination after a fasting period of > 5 h. Dyslipidemia was additionally defined as an LDL/HDL ratio of > 3.5 and/or a triglyceride level of ≥ 150 mg dL
À1
. Individuals taking antihypertensive drugs or with a mean systolic blood pressure of ≥ 140 mmHg or a mean diastolic blood pressure of ≥ 90 mmHg (in the second and third standardized measurements after 8 min and 11 min of rest) were also defined as having hypertension. Self-reported coronary artery disease, myocardial infarction (MI), heart failure, stroke, DVT, PE and peripheral arterial disease indicated a personal history of CVD. A positive family history was defined as MI and/or stroke in male first-degree relatives until the age of 60 years or female first-degree relatives until the age of 65 years.
Categorization of medication
Medications that the study participants were taking were registered on site at the GHS study center by scanning the bar codes from the original packages of the drugs. The medication was classified according to the Anatomical Therapeutic Chemical classification system. The following medication groups were selected for analysis: antithrombotic agents (B01A), aspirin (B01AC56), antilipemic drugs (C10A), antihypertensive drugs (C02), angiotensin-converting enzyme inhibitors (C09), diuretics (C03), angiotensin receptor blockers (C09C), calcium channel blockers (C08), b-blockers (C07), and antineoplastic and immunomodulating agents (L). For the use of oral contraceptives and/or hormone replacement therapy, self-reported information was used. The intake of different medications according to cancer type is shown in Table S1 .
Blood sampling and laboratory measurements EDTA blood samples drawn at inclusion were analyzed on an ADVIA 120 Hematology System (Siemens, Erlangen, Germany) for blood cell count and mean platelet volume. Blood glucose, HbA 1c , C-reactive protein (CRP), total cholesterol, HDL, LDL and triglycerides were determined directly after sampling within 2 h by routine methods in the central laboratory of the University Medical Center in Mainz. D-dimer, coagulation factors expressed as activity based on prothrombin time and/or activated partial thromboplastin time activity assay and von Willebrand factor (VWF) activity were measured in a subsample of the first 5000 of the total study sample of 15 010 GHS individuals. After quality control, results were available for 4962 individuals, including 232 long-term cancer survivors. The measurements were performed in the biomolecular laboratory of the Preventive Cardiology, University Medical Center in Mainz.
Statistical analysis
Normally distributed continuous variables were described by the use of mean and standard deviation (SD), and tested with the t-test; skewed variables were described by the use of median and interquartile range (IQR), and tested with the Mann-Whitney U-test; categorical variables were expressed as absolute and relative frequency, and tested with the chi-squared test. A weighted analysis was applied to adjust for the different age and sex distributions between cancer survivors and the non-cancer group. The non-cancer group was weighted to have the same age and sex distributions as the group of cancer survivors. The results of the weighted group are expressed as relative frequencies (percentages). Multivariable linear regression analysis with laboratory markers as dependent variables adjusted for age, sex, CVRFs and CVD was used to determine the associations with history of cancer used as an independent variable in the models. The association of history of cancer and total mortality with censoring is presented by the use of Kaplan-Meier curves with a log-rank test and by the use of Cox proportional hazards models, adjusted for age, sex, CVRFs, and CVD. Deaths were identified by contacting KommWis, an organization responsible for giving mortality information on the individuals living in the Rhineland-Pfalz region. An individual was considered to be lost to follow-up if the individual was unregistered from the registry offices of Rhineland-Pfalz as a result of moving away and the GHS data administrator could not reach the individual or the individual's relatives for the computer-assisted telephone interview. In this case, the individual was classified as contact lost. Because of the explorative nature of the study, a significance threshold was not defined for P-values. P-values should be interpreted as a continuous measure of statistical evidence. Statistical analysis was performed with software program R, version 3.3.1 (http:// www.R-project.org).
Results
Study population characteristics
The baseline characteristics of individuals who survived cancer for at least 5 years (n = 705) as compared with those without a history of cancer (N = 13626) are shown in Table 1 . The highest prevalence was seen for breast cancer survivors (25.9%), followed by skin cancer survivors (18.01%) and gynecological cancer survivors (17.4%). In age-weighted and sex-weighted analysis (Table 1) , cancer survivors (7.3%) showed a history of VTE more frequently than the general population (5.5%), and no differences were seen in the presence of traditional CVRFs. The frequencies of VTE in individuals with different cancer types are shown in Fig. S1 . Survivors of prostate and hematological cancer showed the highest frequencies of VTE history, at 12.7% and 12.5%, respectively. Regarding comorbidities, chronic obstructive pulmonary disease was more prevalent among cancer survivors than in the population sample (8.9% versus 5.6%, P = 0.00023).
Coagulation and inflammation profile of long-term cancer survivors
An age-weighted and sex-weighted analysis of the laboratory characteristics of individuals with and without a history of cancer is shown in Table S2 . The results showed that fibrinogen levels and antithrombin activity were higher in cancer survivors. Multivariable linear regression analysis for markers of hemostasis with history of cancer as an independent variable in models adjusted for age, sex, CVRFs and CVD confirmed the association with higher fibrinogen levels (b 6.99, 95% confidence interval [CI] 1.16-12.8) and antithrombin activity (b 1.85, 95% CI 0.43-3.27), and showed a positive association with VWF activity (b 5.08, 95% CI 0.02-10.1) for cancer survivors (a summary is shown in Table 2 ; individual models are shown in Table S3 ). As shown in Fig. 1 , the analysis according to type of cancer, adjusted for age and sex, showed increased estimates for fibrinogen levels in gynecological, lung and urinary system cancer survivors, increased estimates for VWF activity in prostate cancer survivors, and increased estimates for antithrombin activity in breast cancer survivors. No significant trend is observed in changes of fibrinogen level and VWF and antithrombin activity levels between different times from cancer diagnosis (Fig. 2) . A detailed description regarding numbers of patients, age range and cancer type per time interval from cancer diagnosis is given in Table S4A ,B. Fifty-two individuals (7.4%) were still receiving antineoplastic agents (Table S1 ). However, no differences were found for coagulation and inflammation parameters between cancer survivors taking these medications and those not taking them.
Cancer survivors and CVD
The clinical and laboratory characteristics of all individuals with established CVD stratified for the presence of a history of cancer are shown in Table 3 . Cancer survivors with CVD were older and included more females. No differences in the presence of CVRFs were observed between the groups. Higher VWF, antithrombin and factor V activity were observed in cancer survivors than in individuals without a history of cancer (Table 3) , with the following differences in the means: VWF, 23.0 (95% CI 7.9-38.1, P = 0.00354); antithrombin, 3.03 (95% CI 0.34-5.73, P < 0.0001); and FV, 5.71 (95% CI 0.08-11.35, P = 0.0471). Weighting of the non-cancer group for the sex and age distributions of the cancer group did not change the relationships observed for VWF (146.6, SD 51.3% versus 128.5, SD 43.4%) and antithrombin (101.8, SD 8.9% versus 99.0, SD 11.6%). Further analysis within the cancer survivor group demonstrated notably higher fibrinogen levels (P = 0.00070) in survivors with CVD.
Survival analysis
A total of 678 deaths were registered during the followup period until August 2017 with a median follow-up Fig. 3A , showed that long-term cancer survivors had worse survival than individuals without a history of cancer. When individuals were additionally stratified for the presence of CVD, the highest mortality was found for individuals with a history of cancer and established CVD, as expected (Fig. 3B) . Cox regression analysis adjusted for age and sex confirmed that a history of cancer increased the risk of death by 73% (hazard ratio CRP, C-reactive protein; CVRF, cardiovascular risk factor; FH, family history; IQR, interquartile range; MI, myocardial infarction; SD, standard deviation; VWF, von Willebrand factor. Statistical analysis was performed with the t-test (mean and SD), the Mann-Whitney U-test (median with IQR) and the chi-squared test for dichotomous variables. P-values of < 0.05 are in bold.
[HR] 1.73, 95% CI 1.35-2.21). Further adjustment for CVRFs did not change the observed association (HR 1.72, 95% CI 1.35-2.20); addition of CVD resulted in an increased risk for individuals with CVD, to 84% (HR 1.84, 95% CI 1.44-2.36). Investigation of the associations of coagulation and inflammation biomarkers with mortality in long-term cancer survivors, as shown in Table S5 , revealed positive relationships of CRP and fibrinogen levels, and FV (%), FVIII (%) and VWF (%) activities, with mortality, independently of age and sex. Table 4 shows the association of a history of cancer, with and without adjustment for the hematological variables, with mortality; this association was also strong.
Discussion
Although the increased risk of CVD in cancer survivors, both survivors of childhood and survivors of adult cancer, is widely recognized [5, 18] , the mechanisms contributing, in particular, to the late risks of CVD are poorly understood and under intensive investigation. Increased levels of endothelial and inflammatory marker proteins have been observed in survivors of testicular cancer and Hodgkin lymphoma in small case-control studies, suggesting their role in accelerated atherosclerosis and an increased risk for CVD [19, 20] . In a comprehensive analysis, adjusting for all potential confounders, we addressed these mechanisms, with a focus on large set of coagulation and hemostatic proteins as well as conventional CVRFs as potential key factors, in longterm cancer survivors from a population-based study.
Our analysis confirmed the important impact of a history of cancer on mortality, independently of classical CVRFs, and further identified fibrinogen and VWF as potential biomarkers in long-term cancer survivors that indicate increased mortality.
We observed that long-term cancer survivors were older and included more females. In an age-weighted and sexweighted analysis, cancer survivors more frequently had a history of VTE than those individuals without a history of cancer in the population sample; no difference was found with regard to prevalent CVRFs. Higher fibrinogen level and VWF activity were strongly associated with long-term survival after cancer, independently of age, sex, CVRFs, CVD, and antithrombotic therapy. This increase was not related to time from cancer diagnosis, as no significant trend was observed for biomarker changes. This finding suggests that increased biomarker levels, which are also observed in cancer survivors with a time from cancer diagnosis of < 5 years, extend long beyond the active cancer stage in long-term cancer survivors.
Elevated plasma fibrinogen levels were implicated in early studies on the pathophysiology of CVD, such as MI and stroke development [21] . An association between plasma fibrinogen and mortality, both vascular and nonvascular mortality, was also shown in a large meta-analysis of 31 prospective studies [22] . A recent large analysis demonstrated that fibrinogen, in addition to conventional risk factors, improves the risk score for the prediction of CVD over a period of 10 years [23] . Furthermore, fibrinogen is known to be involved in tumor angiogenesis, enlargement, and metastasis, and elevated plasma levels of fibrinogen have been associated with tumor progression in many cancer patients [24] [25] [26] . Fibrinogen, a 340-kDa glycoprotein that is synthesized in the liver, is a coagulation protein as well as an acute-phase inflammatory marker. The signal in cancer survivors, as demonstrated in this study, supports the presence of a chronic inflammatory state in these individuals, and implies a potential value of fibrinogen as biomarker for cardiovascular risk assessment that might complement established risk scores.
The observed association with higher VWF activity also supports the relationship with an underlying inflammation and vascular dysfunction. VWF, a large multimeric plasma protein present in endothelial cells, platelets, and subendothelium, is an acute-phase reactant and a marker of endothelial lesions. Increased plasma levels of VWF antigen have been observed in patients with hematological and non-hematological malignancies, e.g. acute lymphoblastic leukemia, colorectal cancer, bladder cancer, and ovarian cancer [27] [28] [29] [30] . Higher levels have been found to correlate with cancer stage and VTE occurrence in cancer patients [31] . VWF also plays a role in hemostasis by binding FVIII and thus protecting the coagulation factor from proteolytic degradation and prolonging its half-life in the circulation. High plasma VWF levels and VWF activity, which is mainly determined by its multimeric size, have been associated with an increased risk of arterial thrombosis [32] . In this study, VWF activity was particularly increased in the cancer survivors among all individuals with CVD. The relevance of fibrinogen levels and VWF activity in cancer survivors may explain the increased risk of death independently of traditional CVRFs and CVD.
The limitations of this study need to be acknowledged. First, the lack of prospective data on cardiovascular events and cause-specific mortality prevents the investigation of inflammation and coagulation markers as predictors for CVD morbidity and mortality. Nevertheless, an important finding was the substantially higher risk of death beyond the acute phase of cancer disease in longterm survivors. Second, the small numbers of distinct cancer types prevented us from drawing conclusions about the specific inflammation and coagulation profiles for each cancer type. The lack of information on survivors' cancer treatment and cancer stage prevented us from analyzing these factors of cancer history in relation to patients' current inflammation and coagulation profile.
The results of this study confirm a proinflammatory and hypercoagulable state in long-term cancer survivors. A history of cancer increases mortality by 80% independently of the presence of traditional cardiovascular risk factors for CVD. These data imply the need for aftercare in cancer patients long beyond the last cycle of chemotherapy. Further investigation is needed to ascertain whether lifelong cardiovascular protection will improve survival in this population. 
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